亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

In vitro activity of imipenem/relebactam and ceftazidime/avibactam against carbapenem-resistant Klebsiella pneumoniae from blood cultures in a University hospital in Serbia

肺炎克雷伯菌 粘菌素 替加环素 肉汤微量稀释 微生物学 头孢他啶/阿维巴坦 头孢他啶 亚胺培南 阿维巴坦 血培养 多重聚合酶链反应 生物 抗生素 最小抑制浓度 抗生素耐药性 聚合酶链反应 细菌 基因 大肠杆菌 生物化学 遗传学 铜绿假单胞菌
作者
Sanja Zornić,Ivana Petrović,Bojana Lukovic
出处
期刊:Acta microbiologica et immunologica Hungarica (Print) [Akademiai Kiado Zrt.]
卷期号:70 (3): 187-192 被引量:1
标识
DOI:10.1556/030.2023.02108
摘要

Abstract The study aimed to investigate prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) blood culture isolates and their susceptibility to two new antibiotics, imipenem/relebactam and ceftazidime/avibactam. Out of 765 isolates recovered from blood cultures in a tertiary care hospital in Serbia between 2020 and 2023, 143 non-repetitive K. pneumoniae strains were included in this study. Minimum inhibitory concentration (MIC) values of the examined antimicrobial drugs was determined by VITEK 2 system, MIC test strip (imipenem/relebactam and ceftazidime/avibactam), and broth microdilution method (tigecycline and colistin). Carbapenemase-encoding genes ( bla KPC , bla OXA-48-like , bla NDM , bla VIM , bla IMP ) were detected using a multiplex-PCR assay, the BioFire-Blood Culture Identification 2-panel. This closed molecular assay is designed for the BioFire® FilmArray® system, enabling automated sample preparation, amplification, detection, and analysis (bioMérieux, France). Results revealed that K. pneumoniae was the most common isolate from blood cultures in 2022. The prevalence of K. pneumoniae was about 11.6% in 2020 and 2021, while in 2022 it raised to over 30%. Also, the frequency of CRKP increased from 11.76% in 2020, through 15.29% in 2021 to 72.94% in 2022. The majority of CRKP carried bla OXA-48-like (60.0%), followed by bla KPC (16.47%), and bla NDM (8.24%) genes, while 14.12% harboured both bla OXA-48-like and bla NDM genes. Only 25.88% of CRKP isolates were resistant to ceftazidime/avibactam, while 51.76% were resistant to imipenem/relebactam and colistin. The rapid spread of CRKP is particularly concerning because therapeutic options are limited to a few antibiotics. While imipenem/relebactam and colistin showed similar antimicrobial activity against CRKP clinical isolates, ceftazidime/avibactam proved to be the most effective antibiotic.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大个应助薄荷味的soda采纳,获得10
41秒前
丘比特应助科研通管家采纳,获得10
1分钟前
LXM完成签到 ,获得积分10
1分钟前
柯语雪完成签到 ,获得积分10
2分钟前
CharlotteBlue应助Hayat采纳,获得30
3分钟前
等于几都行完成签到 ,获得积分10
3分钟前
4分钟前
4分钟前
卑微老大完成签到 ,获得积分10
5分钟前
称心嫣娆完成签到,获得积分10
6分钟前
小二郎应助称心嫣娆采纳,获得10
6分钟前
CharlotteBlue应助pugongying采纳,获得20
7分钟前
秋雪瑶应助qiuxuan100采纳,获得20
7分钟前
energyharvester完成签到 ,获得积分10
8分钟前
脑洞疼应助Joe采纳,获得20
8分钟前
丘比特应助yqc采纳,获得10
8分钟前
lxt819发布了新的文献求助100
8分钟前
韦老虎发布了新的文献求助10
9分钟前
9分钟前
韦老虎发布了新的文献求助10
9分钟前
9分钟前
10分钟前
邓布利多完成签到 ,获得积分10
10分钟前
半糖神仙发布了新的文献求助10
11分钟前
yqc发布了新的文献求助10
11分钟前
11分钟前
称心嫣娆发布了新的文献求助10
11分钟前
11分钟前
qiuxuan100发布了新的文献求助20
11分钟前
孙中华发布了新的文献求助10
11分钟前
半糖神仙完成签到 ,获得积分10
11分钟前
11分钟前
孙中华完成签到,获得积分10
11分钟前
qiuxuan100完成签到,获得积分10
12分钟前
充电宝应助dyfsj采纳,获得10
12分钟前
12分钟前
侯小菊发布了新的文献求助10
12分钟前
Andrewlabeth完成签到 ,获得积分10
13分钟前
Joe发布了新的文献求助20
13分钟前
欣喜破茧完成签到 ,获得积分10
13分钟前
高分求助中
Teaching Social and Emotional Learning in Physical Education 900
Gymnastik für die Jugend 600
Chinese-English Translation Lexicon Version 3.0 500
Electronic Structure Calculations and Structure-Property Relationships on Aromatic Nitro Compounds 500
マンネンタケ科植物由来メロテルペノイド類の網羅的全合成/Collective Synthesis of Meroterpenoids Derived from Ganoderma Family 500
[Lambert-Eaton syndrome without calcium channel autoantibodies] 440
Plesiosaur extinction cycles; events that mark the beginning, middle and end of the Cretaceous 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2384333
求助须知:如何正确求助?哪些是违规求助? 2091268
关于积分的说明 5257866
捐赠科研通 1818144
什么是DOI,文献DOI怎么找? 906953
版权声明 559082
科研通“疑难数据库(出版商)”最低求助积分说明 484248